Qilu Pharmaceutical announced that QLS2401 Injection, a Category 1 innovative biologic independently developed by the company, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), with the proposed indication of metastatic castration‑resistant prostate cancer (mCRPC).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | Center for Drug Evaluation (CDE), NMPA (China) |
| Approval Type | Clinical trial approval – Category 1 innovative biologic |
| Product | QLS2401 Injection |
| Proposed Indication | Metastatic castration‑resistant prostate cancer (mCRPC) |
| Sponsor | Qilu Pharmaceutical (independent development) |
| Announcement Timing | Recently (specific date not disclosed) |
| Next Steps | Initiate clinical evaluation; trial design, sites, and timeline not disclosed |
Drug Profile & Mechanism of Action
- Modality: Trispecific T‑cell engager (TCE) – an engineered biologic designed with best‑in‑class potential per the company.
- Targets: Simultaneously engages PSMA (prostate‑specific membrane antigen) and STEAP1 (six‑transmembrane epithelial antigen of the prostate 1) on tumor cells, plus CD3 on T cells – redirecting cytotoxic T cells to prostate cancer cells through dual tumor‑antigen recognition.
- Rationale for Dual Antigen Targeting: Co‑targeting PSMA and STEAP1 is designed to broaden tumor coverage and address antigen heterogeneity – a key resistance mechanism to single‑antigen therapies in mCRPC.
- Preclinical Differentiation: In cells with medium or low PSMA/STEAP1 expression, QLS2401 demonstrated superior killing activity compared with comparable control molecules – potentially expanding coverage to antigen‑low tumors that escape single‑target agents.
- In Vivo Activity: QLS2401 exhibited robust antitumor activity in both cell line‑derived xenograft (CDX) and patient‑derived xenograft (PDX) tumor models, supporting translational relevance across model systems.
Therapeutic Area Context
- Disease Burden: mCRPC is the advanced, treatment‑resistant stage of prostate cancer that progresses despite androgen‑deprivation therapy, with limited curative options and high mortality.
- T‑Cell Engager Momentum: Bispecific and trispecific TCEs have emerged as a potent modality in hematologic malignancies and are now advancing into solid tumors, where antigen heterogeneity and tumor microenvironment barriers make multi‑target designs attractive.
- Competitive Landscape: PSMA‑directed therapies – including radioligand conjugates, CAR‑T cells, and bispecifics – form an active field in mCRPC; QLS2401’s trispecific PSMA/STEAP1 design positions it as a differentiated entrant.
Market Impact & Outlook
- Pipeline Advancement: The CDE clearance moves QLS2401 into clinical development, adding a first‑in‑pipeline trispecific asset to Qilu Pharmaceutical’s innovation‑drug portfolio in oncology.
- Independent Development Signal: As a Category 1 innovative biologic independently developed by Qilu, QLS2401 underscores the company’s internal biologics and T‑cell engager engineering capabilities.
- Evidence Status: Preclinical findings are qualitative; quantitative efficacy and safety parameters, trial design, and enrollment plans were not disclosed.
- Key Catalysts: First‑patient dosing and early Phase I safety/preliminary efficacy readouts in mCRPC will be the next value inflection points; timing not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory pathway, and commercial potential of QLS2401 Injection. Clinical trial approval authorizes early‑stage evaluation only; the candidate carries substantial risk of failure, and actual results may differ due to trial outcomes, safety findings, and competitive dynamics. This summary is for informational purposes only and does not constitute investment advice.-Fineline Info & Tech
